Global Benign Prostatic Hyperplasia Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Benign Prostatic Hyperplasia Treatment Market is presumed to reach the market size of nearly USD 21.98 BN by 2030 from USD 10.34 BN in 2022 with a CAGR of 8.74% under the study period 2023 - 2030.

BPH stands for benign prostatic hyperplasia, which is a noncancerous cell proliferation inside the prostate gland. The inside of the prostate is first affected. The urethra then gradually becomes compressed as a result of prostatic enlargement. BPH medicines, surgery, and minimally invasive surgery are among viable medical treatments for BPH. These procedures aid in reducing the aberrant prostrate growth or relaxing the smooth bladder muscles.

MARKET DYNAMICS:

The main drivers of advancement are the high incidence of BPH, rising preference for minimally invasive procedures, and rising grants, investments, and funding for the development of innovative treatments. Furthermore, the incidence of BPH is greatly influenced by the ageing population, especially the senior male segment, which drives the demand for pharmaceuticals worldwide. The market for benign prostatic hyperplasia prostate treatment is also anticipated to benefit from the rise in obesity, physical inactivity, and increased awareness of the existence of drugs for treating benign prostatic hyperplasia.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of benign prostatic hyperplasia treatment. The growth and trends of benign prostatic hyperplasia treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the benign prostatic hyperplasia treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

Drug Class (Alpha-Blockers, 5-Alpha-Reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others)
Minimally Invasive Surgeries (Transurethral Resection Of The Prostate (TURP), Transurethral Incision Of The Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others)
Laser Therapy
Others

By End-User

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Benign Prostatic Hyperplasia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the benign prostatic hyperplasia treatment market include Boston Scientific Corporation, Teleflex Incorporated, Endo International Plc, Urologix LLC, LISA Laser, Olympus Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11219538

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BENIGN PROSTATIC HYPERPLASIA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment
- 3.7.2 Market Attractiveness Analysis By End-user
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET ANALYSIS BY TREATMENT

6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Drug Class (Alpha-blockers, 5-Alpha-reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others) Historic and Forecast Sales by Regions
6.5 Minimally Invasive Surgeries (Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others) Historic and Forecast Sales by Regions
6.6 Laser Therapy Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET ANALYSIS BY END-USER

7.1 Overview by End-user
7.2 Historical and Forecast Data
7.3 Analysis by End-user
7.4 Hospitals Historic and Forecast Sales by Regions
7.5 Ambulatory Surgical Centers Historic and Forecast Sales by Regions
7.6 Specialty Clinics Historic and Forecast Sales by Regions
7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT COMPANIES

9.1. Benign Prostatic Hyperplasia Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF BENIGN PROSTATIC HYPERPLASIA TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Boston Scientific Corporation
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Teleflex Incorporated
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Endo International Plc
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Urologix LLC
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. LISA Laser
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Olympus Corporation
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies